We understand that the biggest barrier to our advocacy and the effectiveness of any efforts in liver health is lack of awareness. Our elevated visibility benefits the entire field. From the growing viewership of GLI LIVE, our weekly thought leader talk show which celebrated its 1st anniversary, to launching the first Chronic Liver Disease Trend Report with one of our industry partners at the American College of Gastroenterology meeting, to receiving both the American Association for the Study of Liver Diseases Distinguished Service Advocacy Award and the Global Genes Champion of Hope Founders Award in the same week, we were able to put liver health advocacy in the spotlight like never before. Even more gratifying was to shine the spotlight on the first recipients of the Global Liver Institute Excellence in Health Equity award at our inaugural Leadership in Liver Health Luncheon as part of our #Octoberis4Livers Campaign.

Throughout 2021, Team GLI stayed focused on scaling to meet the evolving needs of the liver community—patients, health care providers, researchers, industry partners, and policymakers—with creativity, caring, and commitment.

Donna R. Cryer, JD
President & CEO
Global Liver Institute

Donna R. Cryer, JD
## Contents

### 05
Board of Directors & Staff

### 21
NASH Programs
- NASH Council 21
- NASH Programs Impact 23

### 09
Office of the CEO

### 11
Special Initiatives of the Office of the CEO
- Diversity, Equity, Belonging 11
- Leadership in Liver Health Luncheon 13
- COVID-19 Response 14

### 15
European Office
- International NASH Day 16
- Culinary Event 19
- Nutristyle App 19

### 21
Liver Health Policy
- Liver Action Network 39
- NASH Externally-Led Patient-Focused Drug Development Meeting 40

### 25
Advanced Advocacy Academy

### 29
Liver Cancers Programs
- Liver Cancers Council 29
- #OctoberIs4Livers 30
- Liver Central 31

### 33
Pediatric and Rare Liver Diseases Programs
- Pediatric and Rare Liver Diseases Council 33
- Inaugural Rare Liver Diseases Month & #RareAware Campaign 34

### 35
Liver Action Network

### 41
Communications
- Social media 42
- GLI LIVE 45

### 46
2020 External Audit Results

### 47
Thought Leadership: CEO Speaking Engagements

### 51
Financial Overview

### 53
Appendix

---

**Our Mission**
To improve the lives of individuals and families impacted by liver disease through promoting innovation, encouraging collaboration, and scaling optimal approaches to help eradicate liver diseases.

**Our Vision**
For liver health awareness to be universal and for liver disease to take its proper place on the global public health agenda consistent with its prevalence and impact.

---

An estimated 1.5 billion persons have chronic liver disease worldwide.¹

---

¹. Clinical Gastroenterology and Hepatology, 2019
Board of Directors

Victor J. Reyes, MBA
Board Chair
Managing Director, Human Capital, Deloitte Consulting LLP

Donna R. Cryer, JD
President & Chief Executive Officer, Global Liver Institute

Lisa Boyette, MD, PHD
Board Treasurer
Vice President of Medical Affairs, Recursion Pharmaceuticals

Brian Munroe
Board Secretary
Vice President Government Affairs, Bausch Health Companies Inc.

Laurie Mobley
Board Development Co-Chair
Senior Vice President, BRG Communications

Amy L. Wright, JD
Board Development Co-Chair
Partner, Taft Stettinius & Hollister

Nicholas Austin, JD
Principal Corporate Legal Counsel, Microsoft, Inc.

Dennis R. Cryer, MD, FAHA
Chief Medical Officer, CryerHealth LLC

Gary Deverman, CFRE
Vice President, NutriStyle

Ben Goodman
Liaison for Legislative Policy & External Communication, Maine Dept. of Economic & Community Development

Monica H. Mcgurk, MBA
Senior Vice President & Chief Global Growth Officer, Kellogg Company

Lewis R. Roberts, MB, CHB, PHD
Professor of Medicine and Consultant, Division of Gastroenterology & Hepatology, Mayo Clinic

Amita Shukla, MBA
Founder & CEO, VitaMita

2021 Staff

Donna R. Cryer, JD
President & Chief Executive Officer

Larry Holden
Chief of Operations

Dhania Nair
Deputy Chief of Operations

Ivy Ahmed
Liver Cancers Program Director

Elisabeth Vogel
Liver Cancers Program Coordinator

Livia Alimena
EU Office Director

Giacomo Donnini
EU Office Manager

Andrew Scott
Policy Director

Gina Bartes
Advanced Advocacy Academy (A3) Program Director

Alexis Story
Advanced Advocacy Academy (A3) Program Coordinator

Jeff McIntyre
NASH Program Director

Catherine Evans
NASH Program Manager

Robert Mitchell-Thain
Pediatric and Rare Liver Diseases Program Director

Nicole Wells
Pediatric and Rare Liver Diseases Program Manager

Dawn Hall
Communications Director

Carrie Gelula
Brand Director

Jill Gerber
Communications Manager

Christine Maalouf
Social Media Manager

Ainsley Amundson
Operations Manager

Operations Coordinator

Leanna Christensen
Calendar Overview

January
President & CEO Donna R. Cryer moderated National Health Council CEO Affinity Group discussion on insights from Pfizer on the COVID-19 vaccine rollout

March
President & CEO Donna R. Cryer spoke at SXSW

May
President & CEO Donna R. Cryer testified at House Oversight and Reform Committee on Organ Procurement
Announced its Liver Action Network (LAN), an affiliation model that provides a structure for the formulation of joint liver health policy and programmatic solutions

April
Worked collaboratively with the liver advocacy community to urge USPSTF to include NASH in the conversation with type 2 diabetes screening and treatment

June
International NASH Day, June 10
Urged FDA & CDC to update their guidelines and regulations to consider additional COVID-19 vaccine doses for immunocompromised individuals

July
First staff retreat

August
Worked collaboratively with the Liver Action Network to urge NIDDK to elevate liver research initiatives within their strategic plan

September
Annual A3 Training Program, September 21-23

October
Annual #OctoberIs4Livers campaign
#BossesWearBurgundy campaign
Leadership in Liver Health Luncheon, October 6
Urged Congress to reintroduce the bicameral and bipartisan LIVER Act (S. 3041 and H.R. 5675)

November
Led the first Externally Led-Patient Focused Drug Development Meeting on NASH

December
Launched Liver Central, a hub for all things liver cancer
Released U.S. NASH Action Plan Scorecard
Since our founding just over seven years ago, GLI has engaged in a range of advocacy activities to direct global attention to liver health commensurate with its prevalence and severity. During an auspicious November, GLI and our CEO received two awards on behalf of the liver disease community in recognition of this impactful work.

The AASLD Distinguished Advocacy Service Award, which recognizes sustained service to the hepatology community by raising awareness, garnering public and legislative support, and promoting liver health and patient care, was awarded to GLI during The Liver Meeting® Digital Experience on November 12.

The RARE Champions of Hope Founder’s Award — which our CEO Donna R. Cryer, JD, received just a week later on November 18 during the Global Genes RARE Health Equity Summit in Philadelphia, Pennsylvania — recognizes founders of impactful organizations in the rare disease community and acknowledges a commitment to connecting, empowering, and inspiring the community and advocating for people living with rare disease.

We are humbled and grateful to be the second annual awardee of each of these honors from longstanding, valued partners of GLI.

Operations Updates

Throughout 2021, GLI invested significantly in upgrading the organization’s technology and infrastructure and in increasing the team’s level of liver health expertise: We transitioned to a new Customer Relations Management (CRM) platform, hired a professional accounting firm, prepared for our first full external audit, introduced a cloud-based project management system, created internal systems to increase efficiency and productivity in human resources, expanded the development team and structures, and prepared for international expansion with our legal team. The organization can expand upon this strong foundation to better serve the needs of the over 1.5 billion liver disease patients around the globe.
Special Initiatives of the Office of the CEO

Diversity, Equity, & Belonging

Health equity is intrinsic to GLI’s mission to improve the lives of individuals and families impacted by liver disease. We recognize the barriers created by longstanding, deeply embedded, systemic issues for liver patients in nearly all circumstances; however, these barriers disproportionately fall upon patients, families, and communities of color. COVID-19 has only magnified this disparity. Certain segments of the population suffer poorer health outcomes than others because of the contributing factors of stigma, economic challenges, immigration status, biases in care delivery, inequity in access to digital technology, and disparate insurance coverage. GLI believes in the importance of diversity, equity, and belonging in both our organization and our work. We are committed to creating structures and cultures that foster confidence and facilitate the engagement of the full and authentic individual.

Our policy agenda reflected our priority of health equity, such as in our support of:

- The Medical Nutrition Equity Act (S. 2013 and H.R. 3783)
- The Building COVID-19 Vaccine Confidence Act of 2021 (H.R. 1268)
- The Improving Social Determinants of Health Act (S.104 and H.R. 379)

Throughout the year, GLI worked collaboratively with other organizations and committees in advancing health equity practices throughout the healthcare system.

- CEO Donna R. Cryer spoke at “Exploring Racial Differences and Disparities in PBC Care,” a roundtable discussion to deepen understanding.

- GLI helped establish the future direction of diversity in rare diseases as part of the steering committee that directs the Rare Disease Diversity Coalition.

- Involvement in Global Genes’ RARE Health Equity Leadership Council allowed our leadership to amplify our principles and practices of diversity, equity, and belonging.

- GLI established its inaugural Excellence in Health Equity award, presented at the fall luncheon to the noteworthy team behind the Black Liver Health Initiative to spotlight their work addressing the historical and new barriers to liver care through engagement with the Black community.
COVID-19 Response

Policy

GLI advocated throughout 2021 for the well-being of patients with liver disease in the midst of the COVID-19 pandemic. We successfully urged the Food and Drug Administration (FDA), the Centers for Disease Control and Prevention (CDC), and other government agencies to update their guidance and regulations to encourage additional COVID-19 vaccine doses for immunocompromised individuals. GLI promoted equity in COVID-19 vaccine distribution for vulnerable populations, both organ transplant recipients and communities of color.

Communication

GLI continued to provide timely updates for patients with liver diseases through our COVID-19 Response Program for Liver Patients. As scientists, researchers, regulators, and the manufacturing supply chain worked to provide vaccinations, treatments, and PPE for society to combat COVID-19, we interpreted guidelines, provided recommendations, and demystified changes for immunocompromised patients, patients with liver diseases, and caregivers through regular educational posts shared on social media, as well as articles posted on our website and shared with our COVID-19 specific mailing list. In 2021, we published 8 COVID-19 articles.

Leadership in Liver Health Luncheon

In tandem with its annual #OctoberIs4Livers campaign, GLI hosted the first Leadership in Liver Health Luncheon at the Hay-Adams on October 6, 2021. The event raised the profile of crucial issues in liver health and showcased successes impacting the liver community. At the luncheon, GLI honored the team behind the Black Liver Health Initiative – Veronica Roye, DNP, FNP-BC; Nicole Golden, DNP, FNP-BC and Monica Nelson-Kone, BSN, RN – with the inaugural Excellence in Health Equity award.

From left to right: Julia Wattacheril, MD, MPH; Awardees Veronica Roye, DNP, FNP-BC, & Nicole Golden, DNP, FNP-BC; Donna R. Cryer, JD; & Rev. Thomas Bowen
European Office

Overview

GLI’s European office is located in Rome, Italy, and facilitates our global partnerships by building relationships with the European Parliament and Commission and with prominent hepatology organizations around the world, such as: Asociación Latinoamericana para el Estudio del Hígado (ALEH), the Asian Pacific Association for the Study of the Liver (APASL), the European Association for the Study of the Liver (EASL), the European Liver and Intestine Transplant Association (ELITA), the European Reference Network for Hepatological Diseases (ERN RARE-LIVER), the Indian National Association for the Study of the Liver (INASL), the European Society for Paediatric Gastroenterology Hepatology and Nutrition (ESPGHAN), the European Society for Organ Transplantation (ESOT), United European Gastroenterology (UEG), and the World Health Organization (WHO).

In expanding our relationship beyond Europe, GLI’s European Office has extended our capacity to interact with regional liver health organizations even further such as: the Canadian Liver Foundation (CLF), the European Cancer Patient Coalition (ECPC), Liver Patients International (LPI) and the PBC Foundation and has established GLI as a trusted partner for campaigns and events.

International #NASHDay

GLI has led International NASH Day since 2019. The WHO European Office for the prevention and control of Noncommunicable Diseases participated in #NASHDay for the first time with a video message underlining the importance of a global event that sheds light on NASH. In addition to AASLD and EASL, 17 of the major hepatology and scientific organizations throughout the world endorsed #NASHDay.

Dr Kremlin Wickramasinghe, MBBS, MSc, DPhil from the European Office of the World Health Organization encourages a worldwide fight against obesity and NASH.

We are proud to collaborate with the WHO Regional Office for Europe.

In 2021, GLI hosted our largest #NASHDay yet!
International

#NASHDay

AT A GLANCE

- Countries: 73
- Partners: 120
- International Endorsements: 17
- Virtual NASH Educational Panels: 8
- International Speakers: 73
- #NASHDay Impressions: 11.5M
- #NASHDay Posts: 4000
- #NASHday Partner Videos: 24
- Brochures in Languages: 16
Culinary Event

International NASH Day 2021 featured the first-ever culinary demonstration on liver-healthy cooking techniques and tips with Celebrity Chef Daniel W. Thomas and GLI President and CEO, Donna R. Cryer, JD.

Nutristyle App

During International NASH Day, GLI and NutriStyle Inc. announced a personalized nutrition app for people living with liver disease, diabetes, and other chronic conditions or who want to maintain good liver health.

International #NASHDay Impact

- GLI and its partners EDUCATED millions of people around the world about NASH.
- Organizations reached out to their LOCAL COMMUNITIES.
- Eight panels brought together leading experts in the NASH field to discuss treatment and care for patients with NASH and prevention strategies.
- Through the Virtual NASH Day Hill Day, GLI and advocates contacted many congressional offices in the U.S. House of Representatives and Senate to support the LIVER Act.

Read the 2021 NASH Day Report, watch the panels and download materials at NASH-day.com
NASH Programs

Overview

GLI’s NASH Programs shine a spotlight on and coalesce a diverse coalition of stakeholders around the urgency of developing mechanisms for addressing the epidemic of NAFLD and NASH worldwide. The NASH Programs also include the Beyond the Biopsy campaign – dedicated to accelerating the acceptance and adoption of non-invasive diagnostics as an alternative to biopsy.

NASH Council

The NASH Programs convenes the NASH Council twice per calendar year and creates workgroups, materials, and campaigns to advance specific concepts and programs. In 2021, the GLI NASH Council grew to over 80 member organizations and expanded its global reach, welcoming new member organizations and partners in pharmacology, diagnostics, and research; as well as medical societies, patient organizations, and NGOs.

Beyond the Biopsy

A multifaceted awareness campaign dedicated to accelerating the acceptance and adoption of non-invasive diagnostics as an alternative to liver biopsy. The initiative encourages advocates to support greater adoption of non-invasive diagnostics by directly influencing legislative, regulatory, and coverage/reimbursement changes.

U.S. NASH Action Plan Scorecard

The U.S. NASH Action Plan 2021 Scorecard, a year-end scorecard for the field of NAFLD and NASH, lists the accomplishments achieved according to the detailed agenda in the U.S. NASH Action Plan. The scorecard is organized by each relevant stakeholder group — patients/carepartners, clinicians, medical societies, patient advocacy organizations, industry, payors, health systems, regulators, and policymakers. While gaps and challenges remain, tracking and acknowledging NASH successes according to the U.S. NASH Action Plan is pivotal for the field to respond on a national scale in 2022 and beyond.

NASH Programs Impact

NASH Core Curriculum

As part of the NASH Core Curriculum – an online resource center to improve clinician understanding of foundational concepts in NASH diagnosis, management, and emerging pharmacologic treatment strategies – NASH Programs created educational materials for the clinician and patient. These materials, NAFLD-NASH 101: Resource for Patients and Caregivers and NAFLD-NASH 101: Resource for Clinicians, are available to supplement the NASH CME program created by GLI and Clinical Care Options, a NASH Council member.

Surfing the NASH Tsunami Podcast:
Driving The Discussion In Fatty Liver Disease

In this weekly podcast, drug developers, investors, researchers, and corporate executives wrestle to understand what is happening in the commercial development of NASH medications. Roger Green, MBA, hosts the podcast, and GLI’s President & CEO Donna R. Cryer, JD; GLI’s Policy Director, Andrew Scott; and GLI’s NASH Program Director, Jeff McIntyre, appear frequently as featured guests.

NASH Diagnostics Forum™

GLI’s NASH Programs, in partnership with the Albert Einstein College of Medicine at the Montefiore Medical Center and NASH Council member Integritas Communications, convened the NASH Diagnostics Forum™ – A Critical Appraisal of Non-Invasive Technologies in NASH: Informing the Future of NASH Diagnosis and Assessment. Nine experts in nonalcoholic steatohepatitis gathered to assess multiple components of the NAFLD/NASH diagnostic process with evidence to support or refute Clinical Assertion Statement on specific issues within NASH diagnostics.
Advanced Advocacy Academy

Overview

Advanced Advocacy Academy (A3) is a year-round program dedicated to training patients and caregivers to be liver health advocates. A3 participants engage in liver health advocacy locally in their communities, federally in the U.S., and globally.

On September 21-23, 2021, GLI successfully held its fifth annual Advanced Advocacy Academy, a training program for liver patients, caregivers, and professionals seeking to elevate their advocacy knowledge and skills needed to advocate for liver health.

The virtual experience was constructed to introduce participants to a broad set of advocacy areas in which they could focus their future endeavors as effective patient advocates. These areas included media, storytelling, research and development, clinical trials, state and federal legislation, support, self care and more. A3 is the first step in GLI’s on-going training and support for liver patients, caregivers, and support professionals, which provides them with the information, skills, and opportunities they need to effectively advocate for liver health.

A3 2021 at a Glance

- **5 Continents**
- **15 Countries**
- **200 Advocates**
- **36 U.S. States**
- **16 Speakers**
- **12 Hours of live online sessions and workshops**

The A3 Class of 2021 increased the total number of A3 participants, over the years, to over 200 from 36 U.S. states and 15 countries.
A3 Impact

- **Empowered** liver advocates to effectively champion the diverse needs and concerns of the liver patient community
- **Convened** a global cohort of liver health advocates to learn advocacy methods and identify intersections of needs and capabilities for patient and caregiver action
- **Instructed** hands-on media training to maximize impact of public speaking opportunities
- **Developed** guides and toolkits to support long-term success in liver health advocacy

Learn more about Advanced Advocacy Academy at [www.globalliver.org/advanced-advocacy-academy](http://www.globalliver.org/advanced-advocacy-academy)

Selected A3 Participant Quotes

"...there is an opportunity for everyone to participate and that is the beauty of it. You can educate yourself at your own pace, you can talk to others and you can grow...."

Lorrinda Davis

"...I think A3 is what finally allowed me to feel comfortable adding patient advocate after my name; beforehand I would say it, but I felt like I didn’t really know what I was doing...I think (after) coming to A3, now I’m very comfortable typing it out: John Mahalchak, Patient Advocate"

John Mahalchak
Liver Cancers Program

Overview
Liver cancer is one of the few cancer types with increasing incidence and mortality rates, with the World Health Organization reporting an estimate of 905,677 new cases and 830,180 deaths from liver cancer globally in 2020. This devastating disease disproportionately impacts marginalized racial and ethnic groups in the US and globally. GLI strives to bring awareness, education, and policy changes to the liver cancer community by amplifying the voices of those impacted. The Liver Cancers Program has fostered multidisciplinary collaborations to accomplish this aim as guided by the Liver Cancers Council with the annual #OctoberIs4Livers campaign and the educational website Liver Central.

Liver Cancers Council
With more than 30 members, GLI’s Liver Cancers Council brings together committed stakeholders across the liver cancer community to share expertise and direction about programs and initiatives addressing all aspects of the liver cancer continuum. The council consists of international patient advocacy organizations, individual healthcare professionals, medical societies, and corporate partners.

#OctoberIs4Livers
Each October, GLI leads #OctoberIs4Livers, the first and only global program dedicated to public awareness, policy, and clinical practice needs to prevent and manage liver cancers. Throughout the month of October, patients, survivors, healthcare providers, medical associations, patient-based organizations, government agencies, community partners and the industry come together to elevate the dialogue about liver cancers and collaborate to improve liver cancer outcomes.
Liver Cancers Program Impact

- **ELEVATED** the global dialogue about liver cancer through a bolstered #Octoberis4Livers education and awareness program
- **CONVENED** global leaders in liver cancer within the Liver Cancers Council to improve the lives of liver patients
- **DEVELOPED** the first State of Liver Cancer Report and accompanying U.S. Congressional briefing to provide up-to-date analysis and inform decision-makers about the burden of liver cancer and path towards equity in care
- **RAISED** the profile of liver health and honored important equity work in liver care through the inaugural Global Liver Institute Leadership in Liver Health Luncheon
- **EXECUTED** a social media campaign entitled #BossesWearBurgundy in which high-profile participants shared photos wearing burgundy to support liver health

Liver Central

In the fourth quarter of 2021, GLI launched Liver Central. This new and innovative website was created to serve as a comprehensive online guide for all things related to liver cancer—both primary and secondary liver cancers. The content on the site was carefully curated to provide valuable information and links to current and relevant research addressing liver cancer. The site is structured to meet the needs of different online audiences including new patients, experienced patients, and clinicians and researchers.

Check out Liver Central at livercentral.org
Pediatric and Rare Liver Diseases Programs

Overview

2021, despite being a particularly challenging year for so many, was a year of growth and solidification within the Pediatric and Rare team. The Pediatric and Rare team doubled in size, with a program manager and a director – both with lived experience in rare liver diseases – working together to maximize potential outreach of the Council.

The department, along with GLI, extended our reach by joining Liver Patients International (LPI), an umbrella organization consisting of many national and international liver patient organizations, with our P&R director being voted in as Vice-Chair of LPI.

Pediatric and Rare Liver Diseases Council

The Pediatric and Rare Liver Diseases Council is a global multi-stakeholder collective of leaders within the pediatric and rare liver disease communities. The council assembles to share an important mix of knowledge, ideas and best practices from patients and patient organizations, clinicians with a special interest, policymakers, and pharmaceutical industry partners. In 2021, the Council included 35 organizations from 8 countries. The Council has a series of working groups with particular specializations – Research, Education, Policy, and International Classification of Diseases 10th Revision (ICD-10) – within the pediatric and rare space. Projects include ICD-10 code nominations, educational brochures, landscape analysis, and more.

Inaugural Rare Liver Diseases Month & #RareAware Campaign

The Pediatric and Rare Liver Diseases team led its first Rare Liver Diseases Month campaign to bring needed attention to the over 100 little-known liver diseases and increase support for these patients around the globe. To achieve these goals, the team prepared an advocate toolkit and resource and fact sheets with registries and organizations and also highlighted rare diseases on GLI LIVE, our weekly educational interview show.

4 GLI LIVE EPISODES

19,394 VIEWS

Social Media Campaign Impressions

837,130

Press Release Potential Reach

981,421,517

Press Release Placements

50

Please visit globalliver.org/rare for more information about the work of the Pediatric and Rare Liver Diseases team.
Liver Health Policy

Overview

In 2021, Global Liver Institute worked at the national and global level to actively shape public policy through:

**ENCOURAGING** collaboration across sectors

Collectively **IMPLEMENTING** legislative and regulatory approaches that are patient centric

**ELEVATING** liver health holistically

**ADVANCING** community goals and initiatives specific to liver health simultaneously

GLI’s Policy Department created opportunities for liver advocates and Liver Action Network organizations to show the groundswell of support for liver health policy through multiple Virtual Advocacy Days as part of International NASH Day and A3.

GLI-led liver advocacy days included more than 100 liver advocates and met more than 80 Congressional Offices representing more than 40 states.

Take action today: [www.globalliver.org/take-action](http://www.globalliver.org/take-action)
2021 Policy Impact

- Successfully elevated liver health within 7 U.S. Federal Agencies and Task Forces and:
  - Prioritized COVID-19 VACCINE doses for immunocompromised individuals
  - Elevated LIVER RESEARCH initiatives
  - Included NASH in the conversation with type 2 diabetes screening, and treatment
  - Highlighted LIVER CANCER AWARENESS MONTH and released a LIVER CANCER statement
  - Worked on the first NASH Externally-Led Patient-Focused Drug Development meeting

GLI encouraged bipartisan, bicameral collaboration and the development of patient-centric legislative packages through:

- PROMOTING REFORM OF THE ORGAN TRANSPLANTATION SYSTEM
- REINTRODUCING A BILL THAT PRIORITIZES THE LIVER, the LIVER Act (S. 3041 and H.R. 5675)
- INTRODUCING THE FIRST OCTOBER IS LIVER CANCER AWARENESS MONTH RESOLUTION
- Collaborating on the eventual reintroduction of the NASH Care Act
- Leading Congressional Briefings on NASH and the State of Liver Cancer
- Advancing the expansion of liver public health programs to address issues such as viral hepatitis

GLI’s Policy Department worked collaboratively with regulators, research agencies, and public health departments on a variety of initiatives with the goal of urging a great recognition of the unique perspective and ability of patients to contribute to the understanding of their condition and treatment management.
Liver Action Network

To meet the needs of a rapidly growing cadre of liver health advocates, capitalize on the eagerness of patients and physicians to be active, and address the needs and opportunities of the community, GLI launched the Liver Action Network (LAN) in May 2021.

Representing more than 40 U.S. states, 2 countries, and 11 community liver advocacy organizations, the LAN is a first-of-its-kind network that provides community member organizations a central structure for the formulation of collective policy positions and programmatic solutions.

LAN member organizations are provided opportunities to use their voices and insights from lived experiences to advance liver health initiatives at local, state, national, and international levels through legislative, regulatory or coverage/reimbursement changes on behalf of all people at risk for or living with liver conditions.

Join our Liver Action Network: globalliver.salsalabs.org/signuptoday/

NASH EL-PFDD

In November, GLI coordinated an externally-led Patient-Focused Drug Development (EL-PFDD) meeting about NASH. This meeting brought patient stories and perspectives about NASH and the drug development process to the attention of policymakers and other stakeholders in the field. Many LAN members participated as patient panelists.

I was diagnosed with metabolic syndrome many years ago before starting my liver journey which started with the bruises... but was never told that this could lead to liver disease.

Bruce Dimmig
Patient Advocate at EL-PFDD meeting

Patients and providers need to urgently know that (a NASH diagnosis) is the beginning of a progressive serious disease and they need to stop it.

Suzanne Maisner
Patient Advocate at EL-PFDD meeting
Communications

Overview

GLI’s Communications Department amplifies the impact of GLI’s programs and facilitates the flow of information between GLI and the public through GLI’s website, social media channels, campaigns, press releases, and more. The department builds and maintains strong personal connections to the patients we serve and their caregivers and families. Additionally, the department maintains relationships with physicians, partners, media, and professionals in the liver health field to raise liver health to its rightful place on the global public health agenda.

Websites

GLI’s websites, GlobalLiver.org and NASHday.com are the ultimate destinations for liver health resources, GLI updates, and world news affecting the liver health community. In November 2021, GLI launched Liver Central, a hub for all things liver cancer to meet the needs of new patients, experienced patients, and clinicians.

Press Releases

As GLI continued to take newsworthy action and launch notable initiatives, its press releases were picked up by many outlets including Yahoo Finance and Yahoo News. From January 2021 to December 2021, GLI sent out 6 press releases on the newswire, reaching millions of readers in the U.S., Canada, and around the world.

Newsletters

GLI continued to send out two monthly newsletters along with its special edition COVID-19 updates to a robust list of subscribers. GLI’s newsletters consistently receive high open and click rates, exceeding the averages for nonprofit organizations.

Social Media

Throughout 2021, GLI’s Communications team supported numerous internal and external campaigns. The team strategized, designed, executed, and monitored GLI’s main internal campaigns.

Pediatric and Rare Liver Diseases’ #RareAware campaign, throughout the month of February

Liver Cancers #October1s4Livers campaign, throughout the month of October

International NASH Day on June 10
#BossesWearBurgundy

throughout the month of October

To honor the millions of people worldwide living with liver disease and spread awareness of these conditions, GLI led a social media campaign entitled #BossesWearBurgundy. Journalists, congressional representatives, health care providers, patient advocates, and others showed their support by posting a picture wearing burgundy and inviting others to join the challenge. (see page 53 for full list of participants)

GLI President and CEO, Donna R. Cryer, JD

GLI uses social media as a tool to disseminate educational material and join global conversations about liver health with patients, physicians, policymakers, partner organizations, and experts in the field to continuously elevate liver health.

Doubled our LinkedIn audience

INCREASED TWITTER FOLLOWING BY ~25%

Hosted live streams and engaged strong audience on Facebook

RE-ESTABLISHED a robust and continuous Instagram presence

CONTINUED TO GROW our repository of liver health educational content on our YouTube channel

Margaret Hoover, Host of Firing Line, PBS Political Commentator, CNN
GLI LIVE

Launched in 2020 as part of our comprehensive COVID-19 response program for liver patients, GLI LIVE provides an outlet to increase connectivity among the liver community through engaging conversation and discussion on a variety of timely topics. Throughout 2021, Donna Cryer, GLI Founder and CEO, continued to host weekly episodes featuring lively dialogue and interesting perspectives from expert guests. Ranging from Members of Congress to physicians, key opinion leaders in the liver health field, liver cancer survivors, and even performers from Broadway’s Hamilton, guests on GLI LIVE provide rich new information and key perspectives relevant to the liver health of individuals, communities, and nations. The show has expanded beyond its origins to cover timely topics across the breadth of the liver health field that align with both GLI and external campaigns. (see full list of episodes and guests on page 54)

IN 2021, GLI HOSTED 37 EPISODES OF GLI LIVE

IN 2020, GLI HOSTED 37 EPISODES OF GLI LIVE

GLI LIVE with Ned Sharpless, MD, Director of the National Cancer Institute of the United States

GLI LIVE with Dr. Martha Dawson, Associate Professor at University of Alabama at Birmingham and President of the National Black Nurses Association

The show streams live every Wednesday at 12 pm ET on Facebook, YouTube, and Twitter.

2020 External Audit Results

INDEPENDENT AUDITORS’ REPORT

To the Board of Directors of Global Liver Institute, Inc., Washington, D.C.

Report on the Financial Statements

We have audited the accompanying statements of financial position of Global Liver Institute, Inc. (a non-profit corporation) as of December 31, 2020, and the related notes. Management’s Responsibility for the Financial Statements

Management is responsible for the preparation and presentation of this financial statement in accordance with accounting principles generally accepted in the United States of America, and for its conformity with the requirements of the Securities and Exchange Commission’s Regulation S-X. Management also has a responsibility to maintain internal control over financial reporting in accordance with standards established by the Public Company Accounting Oversight Board (PCAOB) in the auditor’s report on internal control over financial reporting.

Our Responsibility

Our responsibility is to express an opinion on these financial statements based on our audits. We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (PCAOB). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor’s judgment, including the assessment of the risks of material misstatement of the financial statements. Whether an audit provides a high degree of assurance depends on our judgment in light of the facts and circumstances under which the audit is performed.

We have served as the auditor for the 2020 external audit of GLI and have expressed an opinion on the financial statements of Global Liver Institute, Inc. for the year ended December 31, 2020.
Thought Leadership: CEO Speaking Engagements

WEEKLY HOST
GLI LIVE
RECURRING GUEST
Surfing the NASH Tsunami Podcast

JANUARY 13
Moderated National Health Council CEO Affinity Group discussion on insights from Pfizer on the COVID-19 vaccine rollout

JANUARY 14
Global Genes & Biotech Showcase - RARE Beyond the Square - Speaker

JANUARY 27
Roche’s Global HCC Network - Global Patient Representative

FEBRUARY 2
Veterans Administration Extension for Community Healthcare Outcomes - Hepatology Conference – The Fierce Urgency of Now: How the VA is Uniquely Equipped to Lead in Addressing the Challenges of NASH and Why It Must - Speaker

FEBRUARY 10
Physician’s Weekly Podcast - Response to FDA Briefing on NASH Drug Development - Speaker

FEBRUARY 11
Weinstein Carnegie Philanthropic Group - Social Impact Power Hour on Clubhouse - Rare Diseases and Getting More Awareness for Them - Speaker

FEBRUARY 16
Health Datapalooza & National Health Policy Conference - Chicken Little, the Sky Is (NOT) Falling: Addressing Fears about Patient Access to Health Data - Speaker

MARCH 19
South by Southwest (SXSW) - Bristol Myers Squibb - Healthcare Amid COVID: Virtual Support & Advocacy – Panelist

MARCH 19
Office of the National Coordinator for Health Information Technology (ONC) - A Policy & Technology Workshop on Write-Back APIs – Speaker

MAY 4
House Oversight Committee - Organ Procurement Inquiry Testimony - Speaker

MAY 6
ISPOR Patient Representatives Roundtable - Speaker

MAY 12
Genfit - American Diabetes Association TV Interview - NASH, T2DM, and Patient Identification/Management - Speaker
MAY 18
Research!America - Diversity in Clinical Trials Roundtable - Speaker

MAY 20
National Capital Region - Association of Corporate Counsel (NCR/ACC) Non-Profit Conference - Overseeing Organizational Culture: If Governance isn’t Part of the Solution, It’s Part of the Problem - Speaker

MAY 21
American Board of Internal Medicine - Brain Trust Launch - Speaker

JUNE 2
Managed Healthcare Executive - FDA Oncologic Drugs Advisory Committee - Speaker

JUNE 3
The Post and Courier Newspaper - Organ Procurement - Interview

JUNE 11
Global Genes - Rare Drug Development Symposium - Seizing the Moment: Expanding Impact and Access in Translational Science - Moderator

JUNE 15
Mission: Readiness Podcast - Liver Health Episode - Speaker

JUNE 17
Bayer - LinkedIn Live - The new healthcare intelligence: How digitalization empowers people to manage their health - Panelist

JUNE 23
HepDynamics - Digital International Liver Congress 2021 - What Patients and Advocates Can Expect - Interview

JUNE 25
Biotechnology Innovation Organization (BIO) - CT Diversity Summit - The Imperative of Community & Patient Engagement: Building Trust in & Awareness of Opportunities to Participate in Clinical Trials - Opening Remarks + Moderator

JUNE 30
Drug Information Association (DIA) - Global Annual Meeting - The Intersection of Health Equity and Personalized Medicine - Speaker

JULY 12
HepDynamics - Surfing the NASH Tsunami - Optimizing Trial Recruitment by Broadening our Field of Vision - Host

JULY 15
WCG Clinical - Interview with Global Liver Institute - Speaker

JULY 20
Genentech - National Medical Association 2021 - Driving for health equity through early screening - Speaker

AUGUST 12
Proceedings of the National Academy of Sciences - Rise of decentralized, virtual clinical trials in the wake of the Covid-19 pandemic - Interview

AUGUST 19
Axdev Group - Study in the Field of NAFLD, NASH, and Advanced Fibrosis - Interviewee

AUGUST 23
Novartis - Expert Patient PRO Advisory Board - Reviewer

SEPTEMBER 3
Horizon Therapeutics & MIT Solve - The Horizon Prize - Judge

SEPTEMBER 17
National Committee for Quality Assurance (NCQA) - NASH Roundtable - Improving Quality of Care for Nonalcoholic Steatohepatitis (NASH) Disease - Panelist

SEPTEMBER 28
Global Genes - RARE Patient Advocacy Summit - From Awareness to Participation: Bridging Gaps in Representation in Research - Speaker

OCTOBER 22
Sanofi - Global Liver Forum (GLF) Webinar - Efforts for Early Detection and Screening of NAFLD, and Global Burden of NAFLD - Speaker

NOVEMBER 14
AASLD - The Liver Meeting - Grit, Grace, Gratitude & Resilience: What You Wish Your Doctors Knew About You - Speaker

NOVEMBER 17
Healthy Churches 2030 Annual Conference - Demanding a Seat at the Clinical Trials Table: Why Inclusion Matters! - Panelist
Financial Overview

**Assets**
- Cash and Cash Equivalents: $154,409
- Accounts Receivable: $135,810
- Other Current Assets: $22,645
- Fixed Assets-Net: $17,190
- Other Assets: $—
- **Total Assets**: $330,054

**Liabilities and Net Assets**
- A/P and accrued expenses: $294,165
- Deferred Revenue: $470,568
- Loan Payable - PPP loan: $—
- **Total Liabilities**: $764,733
- Net Assets Total: $434,679
- **Liabilities and Net Assets**: $330,054

**Revenue**
- Memberships: $758,207
- Contributions-Unrestricted: $332,263
- Contributions-Restricted: $229,000
- Sponsorships: $482,000
- Other Revenues: $41,231
- Gain on Debt Extinguishment-PPPL: $64,880
- **Total Revenue**: $1,907,581

**Expenses**
- Programs and Grants: $1,821,739
- General and Administrative: $543,105
- Fundraising: $58,177
- **Total Expenses**: $2,423,022

**Change in Net Assets**
- **Net Assets, Beginning of Year**: $80,763
- **Net Assets, End of Year**: $434,679
- **Change in Net Assets**: $353,916

**GLI Revenue Types**
- Membership Dues: 39.7%
- Sponsorships: 27.3%
- Grants: 14.9%
- Individual Contributions: 6.1%
- Program Service Fee: 2.9%
- Misc Revenue: 12.0%
- Restricted Funds: 3.4%
- Restricted Funds: 2.1%
- Program Service Fee: 3.4%
- Restricted Funds: 1.9%
- Restricted Funds: 0.5%

**Expenses by Program**
- Liver Cancers: 37.5%
- NASH: 28.8%
- Gain on Debt Extinguishment-PPPL: 3.4%
- Pediatric and Rare Liver Diseases: 4.7%
- International NASH Day: 6.1%
- Advanced Advocacy Academy: 7.3%
- Policy: 9.2%
- Administrative: 2.9%
#BossesWearBurgundy participants

- Cecilia Abbot: First Lady of Texas
- Andrea Michelle Alexander: Chief People Officer, Rent the Runway
- Steve Benjamin: Mayor of Columbia, South Carolina
- Michael Betel: President & Founder, Fatty Liver Alliance
- Diane Brockmeier: President and CEO, Mid-America Transplant
- Katie Brown: Cancer Survivor, Writer, & Patient Advocate
- Rep. Tony Cardenas: Member, U.S. House of Representatives (D-CA)
- James E. Clyburn: Majority Whip, U.S. House of Representatives (D-SC)
- Jean Jones: Patient Advocate
- Teri P. Cox: President, Cox Communication Partners
- Mario Díaz-Balart: Member, U.S. House of Representatives (D-FL)
- Senator Bill Frist: Member, U.S. House of Representatives (R-SC)
- Kristine Gauvreau Urea: Executive Vice President, Market Performance Group
- Lt. Gov. Adam Gregg: Iowa’s 47th Lieutenant Governor
- Margaret Hoover: Host of Firing Line, PBS
- Charisse Hughes: SVP & Global CMO at Kellogg Company
- Dr. Jackie Kassouf Maalouf: President & Founder, National Diabetes Organization - DiaLab
- Robin Kelly: Member, U.S. House of Representatives (D-IL)
- Monica McGurk: Chief Global Growth Officer, Kellogg
- Raquel Peck: Founder & Director, Clarion I.
- Eva Pilgrim: Co-Anchor, Good Morning America
- Bill Remak: Chair of the Board of Directors/CEO, TriSalus Life Sciences
- Tony Sanneh: American retired professional soccer player
- Bakari Sellers: Political Analyst, CNN
- Parul Sood: Deputy General Manager Marketing, Zydus

Institutions

- Kingman Regional Medical Center, Kingman, AZ
- Mental Illness Recovery Center, Inc. (MIRCI), Columbia, SC
- TriSalus Life Sciences, Westminster, CO

GLI LIVE episodes and guests

- European Liver Research, Education, and Policy
  Prof. Thomas Berg, Head Division of Hepatology, University Medical Center Leipzig, Germany and Secretary General, European Association for the Study of the Liver (EASL)

- Liver Health Policy in 2021
  Tamar Taddei, MD, leader of the AASLD Public Policy Committee

- Dry January
  Chris Boyd, co-founder of Dry January

- Rare Disease Month: Lysosomal Acid Lipase Deficiency (LAL-D)
  Don P. Wilson, MD, Pediatric Endocrinologist, Cook Children’s Medical Center and Secretary of Foundation of the National Lipid Association

- Rare Disease Month: Alagille Syndrome
  Cher Bork, Executive Director of Alagille Syndrome Alliance

- Rare Disease Month: Primary Sclerosing Cholangitis (PSC)
  Marco Cartone, MD, Hepatologist, University of Milan-Bicocca, European Reference Network (ERN)’s clinical lead for cholestatic liver diseases

- Rare Disease Month: Primary Bilary Cholangitis (PBC)
  Cynthia Levy, MD, Hepatologist, Associate Director, Schiff Center for Liver Diseases, University of Miami

- The Connection Between Liver Health and Kidney Health
  Richard Knight, President, American Association of Kidney Patients

- NASH, Obesity, and Liver Health
  Rotonna Carr, MD, FACP; Associate Professor of Medicine, Hospital of the University of Pennsylvania

Policy Partners: Advocating for Liver and Kidney Health
- Rachel Mayer, Senior Director of Policy and Government Affairs, American Society of Nephrology
- David White, Regulatory and Quality Officer, American Society of Nephrology
- Zachary Kribbs, Senior Government Affairs Specialist, American Society of Nephrology
- Andrew Scott, Director, Policy, Global Liver Institute

Why Weight Can’t Wait
- William Dzitz, MD, Director, Summer M. Redstone Global Center for Prevention and Wellness, Milken Institute School of Public Health, George Washington University and Director, STOP Obesity Alliance, The George Washington University

Overcoming Weight Bias and Stigma
- Joe Nadglowski, President & CEO, Obesity Action Coalition

Through the Lens of Kidney Health: Advocacy in Action
- Troy Zimmerman, Special Projects Director, National Kidney Foundation

Constructing a more Equitable Kidney Health Agenda
- LaVona Burton, President & CEO, American Kidney Fund

Stories of Tragedy & Triumph
- Ms. Daloris Benton Evans, Donor Mother
- Cara Kass, MD, Emergency Medicine Physician & Founder of FemInEM

The Evolution of COVID-19 Response: Looking Back & Moving Forward
- Martha A. Dawson, DNP, RN, FACHE, President, National Black Nurses Association

GI Cancer Research and Patient Advocacy
- Mark Lewis, MD, Director, Gastrointestinal Oncology, Intermountain Healthcare

Physical Activity and NASH
- Jonathan Shine, MD, MSc, FACP, Director of Research, Penn State Liver Center

Hepatitis Testing Day
- Su Wang, MD, MPH, President, World Hepatitis Alliance
Patients Changing the Conversation on Liver Disease
Kendal Ciesemier, NGO Founder, Writer, Reporter
Nora Logan, Writer, Patient Advocate

Liver Action Network Launch
Scott Suckow, Liver Coalition of San Diego
Farrah Douglas, Liver Wellness Foundation
Teresa Davidson, Mid-South Liver Alliance

Setting the Global NASH Agenda in NASH
Prof Jeff Lazarus, EASL's International Liver Foundation Vice-Chair

Every liver, every time: Best Practices in Organ Donation and Recovery
Diane Brockmeier, President & CEO, Mid-America Transplant
Kevin Lee, Chief Organ Operations, Mid-America Transplant

Liver Healthy Eating: There’s an App for That
Todd Abro, Co-Founder & CEO, NutriStyle Inc.
Scott Murdoch, PhD, RD, Co-Founder & CNP, NutriStyle Inc.

Self-care Summer: A Chance to Reset and Refresh
Donna R. Cryer, President & CEO, Global Liver Institute

World Hepatitis Day
Michael Ninburg, Executive Director, Hepatitis Education Project

What Should Transplant Recipients Know About COVID-19
Dr. Deapal Kumar, President-Elect, American Society of Transplantation

Meet the A3 Advocates
Lorrinda Gary Davis, Founder & President, Trio-Oklahoma Organization
John Mahalchak, Patient Advocate

Transplant Survivorth
Warren Maley, MD, Director, Jefferson Transplant Institute
Nicole Wells, Transplant Recipient, Pediatric & Rare Liver Diseases Program Manager, Global Liver Institute

The National Cancer Act at 50 & the Prospects for Ending Liver Cancer
Dr. Norman E. Sharpless, Director, National Cancer Institute

Cancer Advocacy and Patient Support #October4Livers
Matthew Zachary, Advocate, Podcast Hero, Founder of OffScrip Media & Stupid Cancer

Addressing Liver Cancer Disparities in the American Indian & Alaska Native Communities #October4Livers
Bahmoush Momin, DrPH, MS, MPH, Health Scientist, Center for Disease Control
Stephanie Melkonian, PhD, Epidemiologist, Center for Disease Control

Breakthrough Treatment Options in Liver Cancer #October4Livers
Dr. Maria Reig, Head of Barcelola Clinic Liver Cancer (BCLC Group)

Booster Shots & COVID-19 Updates
Robert Fontana, MD, FAASLD, Professor of Internal Medicine, Medical Director of Liver Transplantation

Liver Health & National Security - A Tribute to Veterans Day
Major General (Ret.) Michael S. Hall, U.S. Air Force

NAFLD, NASH & Diabetes
Brent Tels, MD, Gastroenterology, Internal Medicine, Hepatology, SLUcare Missouri

GLI LIVE meets NASH Tsunami
Roger Green, Roger Green, Managing Principal - HEP Dynamics, Executive Producer & Host of Surfing the NASH Tsunami

Introducing Liver Central
Steven Katz, MD, FACS, Chief Medical Officer, TriSalus Life Sciences

Picking up Where we Left off
Ekaterina (Katy) Samli, MPA, MPH, PMP, Project Manager, Integrated Care, MotoPore Care Management

Donate Today!
Patients Changing the Conversation on Liver Disease
Kendal Ciesemier, NGO Founder, Writer, Reporter
Nora Logan, Writer, Patient Advocate

Liver Action Network Launch
Scott Suckow, Liver Coalition of San Diego
Farrah Douglas, Liver Wellness Foundation
Teresa Davidson, Mid-South Liver Alliance

Setting the Global NASH Agenda in NASH
Prof Jeff Lazarus, EASL's International Liver Foundation Vice-Chair

Every liver, every time: Best Practices in Organ Donation and Recovery
Diane Brockmeier, President & CEO, Mid-America Transplant
Kevin Lee, Chief Organ Operations, Mid-America Transplant

Liver Healthy Eating: There’s an App for That
Todd Abro, Co-Founder & CEO, NutriStyle Inc.
Scott Murdoch, PhD, RD, Co-Founder & CNP, NutriStyle Inc.

Self-care Summer: A Chance to Reset and Refresh
Donna R. Cryer, President & CEO, Global Liver Institute

World Hepatitis Day
Michael Ninburg, Executive Director, Hepatitis Education Project

What Should Transplant Recipients Know About COVID-19
Dr. Deapal Kumar, President-Elect, American Society of Transplantation

Meet the A3 Advocates
Lorrinda Gary Davis, Founder & President, Trio-Oklahoma Organization
John Mahalchak, Patient Advocate

Transplant Survivorth
Warren Maley, MD, Director, Jefferson Transplant Institute
Nicole Wells, Transplant Recipient, Pediatric & Rare Liver Diseases Program Manager, Global Liver Institute

The National Cancer Act at 50 & the Prospects for Ending Liver Cancer
Dr. Norman E. Sharpless, Director, National Cancer Institute

Cancer Advocacy and Patient Support #October4Livers
Matthew Zachary, Advocate, Podcast Hero, Founder of OffScrip Media & Stupid Cancer

Addressing Liver Cancer Disparities in the American Indian & Alaska Native Communities #October4Livers
Bahmoush Momin, DrPH, MS, MPH, Health Scientist, Center for Disease Control
Stephanie Melkonian, PhD, Epidemiologist, Center for Disease Control

Breakthrough Treatment Options in Liver Cancer #October4Livers
Dr. Maria Reig, Head of Barcelola Clinic Liver Cancer (BCLC Group)

Booster Shots & COVID-19 Updates
Robert Fontana, MD, FAASLD, Professor of Internal Medicine, Medical Director of Liver Transplantation

Liver Health & National Security - A Tribute to Veterans Day
Major General (Ret.) Michael S. Hall, U.S. Air Force

NAFLD, NASH & Diabetes
Brent Tels, MD, Gastroenterology, Internal Medicine, Hepatology, SLUcare Missouri

GLI LIVE meets NASH Tsunami
Roger Green, Roger Green, Managing Principal - HEP Dynamics, Executive Producer & Host of Surfing the NASH Tsunami

Introducing Liver Central
Steven Katz, MD, FACS, Chief Medical Officer, TriSalus Life Sciences

Picking up Where we Left off
Ekaterina (Katy) Samli, MPA, MPH, PMP, Project Manager, Integrated Care, MotoPore Care Management

Donate Today!
Global Liver Institute (GLI) is a patient-driven 501(c)3 nonprofit organization headquartered in Washington, DC, with offices in the EU and UK, founded in the belief that liver health must take its place on the global public health agenda commensurate with the prevalence and impact of liver disease and the importance of liver health to well-being. GLI promotes innovation, encourages collaboration, and supports the scaling of optimal approaches to improve research, care, and policy. By bringing together more than 200 community-based, national, and international organizations across its Councils, Campaigns, and events, GLI equips advocates to identify and solve the problems that matter to liver patients. Follow GLI on Twitter, Facebook, Instagram, LinkedIn, and YouTube.

Donate Today!

We put your contribution to work!